IGF1 and cancer: To assess whether IGF2 is required for the maintenance of CSC property, Hep3B cells were treated with chromeceptin (also known as 94G6) that is a synthetic small benzochromene derivative and inhibits the IGF signaling pathway in cancer including HCC21.